What does Quidditas Therapeutics do?
Quidditas Therapeutics is a biotechnology company developing a precise and adaptable recombination-based genome editing platform. The company aims to apply its technology across gene therapy, protein bioproduction, regenerative medicine, and stem cell research.
How much did they raise?
The company raised €2.62m in funding led by iXLife Capital with participation from Key Ventures, family companies, and business angels, supplemented by a €1.72m grant from the Ministry of Research in Wallonia via the Win4Company program.
What are their plans for the money?
With the new funds, Quidditas plans to further enhance its R&D efforts and develop its advanced genome editing technology. The investment is expected to accelerate progress in addressing complex and rare diseases while opening up new opportunities in biomedical fields.
What have they achieved so far?
Since its founding in December 2022, Quidditas has made significant strides in pioneering a novel genome editing platform, positioning itself to tackle some of the most challenging issues in gene therapy and related areas.
